vida: extract claims from 2026-04-22-healthverity-glp1-trends-2025-persistence-data

- Source: inbox/queue/2026-04-22-healthverity-glp1-trends-2025-persistence-data.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks.md

@@ -10,12 +10,17 @@ agent: vida
 scope: causal
 sourcer: IAPAM
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
-supports:
-- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
-reweave_edges:
-- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12
+supports: ["GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales"]
+reweave_edges: ["GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12"]
+related: ["glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support"]
 ---
 
 # GLP-1 receptor agonists produce nutritional deficiencies in 12-14 percent of users within 6-12 months requiring monitoring infrastructure current prescribing lacks
 
-A large cohort study of 461,382 GLP-1 users found that 12.7% developed new nutritional deficiency diagnoses at 6 months of therapy, rising to 13.6% for vitamin D deficiency by 12 months. Deficiencies in iron, B vitamins, calcium, selenium, and zinc also increased over time. The mechanism is straightforward: GLP-1 receptor agonists suppress appetite broadly, reducing total caloric intake including micronutrient-rich foods. This is not a rare adverse effect but a common one affecting more than one in eight users. The clinical significance is underscored by the first formal multi-society guidance (AHA/ACLM/ASN/OMA/TOS joint advisory in American Journal of Clinical Nutrition, 2025) specifically addressing nutritional monitoring and supplementation for GLP-1 users. IAPAM clinical practice updates from October 2025 through February 2026 document practitioners reporting increasing presentations of GLP-1-related complications including muscle mass loss (sarcopenia), hair loss (telogen effluvium from protein/micronutrient depletion), and bone density concerns. The gap is operational: GLP-1 is being prescribed at unprecedented scale with a simple 'inject and lose weight' narrative, but the medical system lacks the monitoring infrastructure to systematically catch and correct these deficiencies before they produce secondary health effects that may undermine the metabolic benefits of weight loss.
+A large cohort study of 461,382 GLP-1 users found that 12.7% developed new nutritional deficiency diagnoses at 6 months of therapy, rising to 13.6% for vitamin D deficiency by 12 months. Deficiencies in iron, B vitamins, calcium, selenium, and zinc also increased over time. The mechanism is straightforward: GLP-1 receptor agonists suppress appetite broadly, reducing total caloric intake including micronutrient-rich foods. This is not a rare adverse effect but a common one affecting more than one in eight users. The clinical significance is underscored by the first formal multi-society guidance (AHA/ACLM/ASN/OMA/TOS joint advisory in American Journal of Clinical Nutrition, 2025) specifically addressing nutritional monitoring and supplementation for GLP-1 users. IAPAM clinical practice updates from October 2025 through February 2026 document practitioners reporting increasing presentations of GLP-1-related complications including muscle mass loss (sarcopenia), hair loss (telogen effluvium from protein/micronutrient depletion), and bone density concerns. The gap is operational: GLP-1 is being prescribed at unprecedented scale with a simple 'inject and lose weight' narrative, but the medical system lacks the monitoring infrastructure to systematically catch and correct these deficiencies before they produce secondary health effects that may undermine the metabolic benefits of weight loss.
+
+## Supporting Evidence
+
+**Source:** HealthVerity 2025 safety signal analysis
+
+HealthVerity analysis identifies nutrient deficiencies as emerging safety concern alongside GI effects (50% nausea, 33% diarrhea), psychiatric effects, and respiratory risks in asthma patients. GI effects are primary discontinuation driver.

domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md

@@ -10,16 +10,10 @@ agent: vida
 scope: causal
 sourcer: Tzang et al. (Lancet eClinicalMedicine)
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
-related:
-- glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks
-reweave_edges:
-- glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks|related|2026-04-09
-- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12
-- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement|challenges|2026-04-14
-supports:
-- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
-challenges:
-- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement
+related: ["glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms"]
+reweave_edges: ["glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks|related|2026-04-09", "GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12", "Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement|challenges|2026-04-14"]
+supports: ["GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales"]
+challenges: ["Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement"]
 ---
 
 # GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation
@@ -31,3 +25,10 @@ Meta-analysis of 18 randomized controlled trials (n=3,771) demonstrates that GLP
 **Source:** WHO December 2025 guideline conditional framing
 
 WHO's conditional recommendation acknowledges 'limited long-term evidence' and 'durability of effects unclear' as reasons for not issuing a strong recommendation. The guideline's caution about discontinuation effects aligns with the 28-52 week reversal timeline documented in clinical trials.
+
+
+## Supporting Evidence
+
+**Source:** HealthVerity 2025 persistence cohort analysis
+
+Real-world discontinuation data shows 22% of semaglutide users and 16% of tirzepatide users stopped within first year, with only 14% persisting at three years. Combined with known 28-week metabolic rebound, this means approximately 14% of initiators (or 1.7% of eligible obese/overweight adults) receive durable metabolic benefit.

domains/health/glp1-long-term-persistence-ceiling-14-percent-year-two.md

@@ -10,14 +10,16 @@ agent: vida
 scope: structural
 sourcer: BCBS Health Institute
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[AI middleware bridges consumer wearable data to clinical utility because continuous data is too voluminous for direct clinician review]]"]
-related:
-- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
-- GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management
-reweave_edges:
-- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation|related|2026-04-09
-- GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management|related|2026-04-09
+related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x", "divergence-glp1-economics-chronic-cost-vs-low-persistence"]
+reweave_edges: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation|related|2026-04-09", "GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management|related|2026-04-09"]
 ---
 
 # GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements
 
-Despite the near-doubling of year-one persistence rates, Prime Therapeutics data shows only 14% of members newly initiating a GLP-1 for obesity without diabetes were persistent at two years (1 in 7). Three-year data from earlier cohorts shows further decline to approximately 8-10%. The striking divergence between year-one persistence (62.7% for semaglutide in 2024) and year-two persistence (14%) suggests that the drivers of short-term adherence improvement—supply access, initial motivation, dose titration support—are fundamentally different from the drivers of long-term dropout. This creates a structural ceiling on long-term adherence under current support infrastructure. The mechanisms that successfully doubled year-one persistence (supply normalization, improved patient management) do not translate to sustained behavior change, suggesting that continuous monitoring, behavioral support, or different care delivery models may be required to address the long-term adherence problem. This persistence ceiling is the specific mechanism by which the population-level mortality signal from GLP-1 therapy gets delayed despite widespread adoption.
+Despite the near-doubling of year-one persistence rates, Prime Therapeutics data shows only 14% of members newly initiating a GLP-1 for obesity without diabetes were persistent at two years (1 in 7). Three-year data from earlier cohorts shows further decline to approximately 8-10%. The striking divergence between year-one persistence (62.7% for semaglutide in 2024) and year-two persistence (14%) suggests that the drivers of short-term adherence improvement—supply access, initial motivation, dose titration support—are fundamentally different from the drivers of long-term dropout. This creates a structural ceiling on long-term adherence under current support infrastructure. The mechanisms that successfully doubled year-one persistence (supply normalization, improved patient management) do not translate to sustained behavior change, suggesting that continuous monitoring, behavioral support, or different care delivery models may be required to address the long-term adherence problem. This persistence ceiling is the specific mechanism by which the population-level mortality signal from GLP-1 therapy gets delayed despite widespread adoption.
+
+## Supporting Evidence
+
+**Source:** HealthVerity 2025 GLP-1 Trends analysis
+
+HealthVerity real-world pharmacy claims data confirms 14% three-year persistence among GLP-1 initiators, consistent with the established year-two ceiling. This represents cohort data from early 2024 initiators tracked through 2025.

domains/health/glp1-year-one-persistence-doubled-2021-2024-supply-normalization.md

@@ -10,12 +10,17 @@ agent: vida
 scope: correlational
 sourcer: BCBS Health Institute
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[divergence-glp1-economics-chronic-cost-vs-low-persistence]]"]
-supports:
-- GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements
-reweave_edges:
-- GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements|supports|2026-04-09
+supports: ["GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements"]
+reweave_edges: ["GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements|supports|2026-04-09"]
+related: ["glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-long-term-persistence-ceiling-14-percent-year-two", "semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints"]
 ---
 
 # GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management
 
-BCBS Health Institute and Prime Therapeutics analyzed real-world commercial insurance data showing one-year persistence rates for obesity-indicated, high-potency GLP-1 products increased from 33.2% in 2021 to 34.1% in 2022, 40.4% in 2023, and 62.6% in 2024. Semaglutide (Wegovy) specifically tracked nearly identically: 33.2% (2021) → 34.1% (2022) → 40.0% (2023) → 62.7% (2024). Adherence during the first year improved from 30.2% (2021) to 55.5% (2024 H1). The report attributes this improvement to two primary drivers: resolution of supply shortages that plagued 2021-2022 and 'improved patient management' (though the specific mechanisms are not detailed). This represents a genuine shift in the short-term adherence pattern and compresses the population-level signal timeline for GLP-1 impact. However, this data is limited to commercial insurance populations, which have better access and support than Medicaid, Medicare, or uninsured populations, suggesting the improvement may not generalize to the populations most in need of obesity treatment.
+BCBS Health Institute and Prime Therapeutics analyzed real-world commercial insurance data showing one-year persistence rates for obesity-indicated, high-potency GLP-1 products increased from 33.2% in 2021 to 34.1% in 2022, 40.4% in 2023, and 62.6% in 2024. Semaglutide (Wegovy) specifically tracked nearly identically: 33.2% (2021) → 34.1% (2022) → 40.0% (2023) → 62.7% (2024). Adherence during the first year improved from 30.2% (2021) to 55.5% (2024 H1). The report attributes this improvement to two primary drivers: resolution of supply shortages that plagued 2021-2022 and 'improved patient management' (though the specific mechanisms are not detailed). This represents a genuine shift in the short-term adherence pattern and compresses the population-level signal timeline for GLP-1 impact. However, this data is limited to commercial insurance populations, which have better access and support than Medicaid, Medicare, or uninsured populations, suggesting the improvement may not generalize to the populations most in need of obesity treatment.
+
+## Extending Evidence
+
+**Source:** HealthVerity 2025, real-world pharmacy claims
+
+Year-one persistence for Wegovy/Zepbound initiators reached 63% in early 2024 cohort, up from 40% in 2023. This represents continued improvement beyond the 2021-2024 doubling trend, suggesting adherence programs and prescribing practices are having measurable impact on first-year retention even as the three-year ceiling persists.